Reviewer's report

**Title:** Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism.

**Version:** 4  **Date:** 19 June 2012

**Reviewer:** Jamshid S Sorouri Khorashad

**Reviewer's report:**

I have a few comments which I would like to be cleared or corrected by the authors:

1. The applied dosage of these drugs imatinib, nilotinib and dasatinib, should have been adjusted in accordance with the difference in their potencies. The authors compared equal amount of drugs for these three AKIs in their investigations while the equivalent potent dose of these AKIs should have been used.

2. The information in figure 1D needs to be reviewed (viable cells percentage after treatment by 1uM imatinib does not look to be correct compared to the same dose of dasatinib). There is not enough information about the duration of the exposure to drugs in the figure 1 legends. There is no SD bar in dasatinib column of the figure 1B.

3. In figure 1A different dosage of imatinib and dasatinib was used while in figure 1B the amount of imatinib and dasatinib was similar. The authors need to explain the reason for the difference between these two experiments. Again it raises the concern over using equal potent amount of these two drugs.

4. The authors need to rephrase the results related to figure 2. It is better to avoid using a certain amount of drugs for all “AKIs”. 1uM imatinib has a very different potency from 1uM nilotinib and 1uM nilotinib has a different potency from 1uM dasatinib. Therefore the phrase “AKIs at 1uM” as used in section two of the results is not accurate.

5. There is a problem with labeling of figure 6. There are two figure numbers in the same page.

**Level of interest:** An article whose findings are important to those with closely related research interests

**Quality of written English:** Acceptable

**Statistical review:** Yes, but I do not feel adequately qualified to assess the statistics.

**Declaration of competing interests:**
I declare that I have no competing interests